Endeavor Biomedicines, Inc.
Endeavor BioMedicines is a clinical-stage biotechnology company developing transformational medicines for life-threatening diseases.
Funding history
About Endeavor Biomedicines, Inc.
How much funding has Endeavor Biomedicines, Inc. raised?
Endeavor Biomedicines, Inc. has raised $132.6M in total funding. The most recent round was Series C.
Where is Endeavor Biomedicines, Inc. headquartered?
Endeavor Biomedicines, Inc. is headquartered in San Diego, CA.
What does Endeavor Biomedicines, Inc. do?
Endeavor BioMedicines is a clinical-stage biotechnology company developing transformational medicines for life-threatening diseases.
What problem does Endeavor Biomedicines, Inc. solve?
Patients with life-threatening fibrotic lung diseases like idiopathic pulmonary fibrosis (IPF) lack treatments that do more than slow disease progression.
What's Endeavor Biomedicines, Inc.'s solution?
Endeavor is a clinical-stage biotech developing taladegib (ENV-101), a Hedgehog signaling pathway inhibitor, to treat fibrotic lung disease including IPF.
What makes Endeavor Biomedicines, Inc. different?
Its Phase 2a trial data showed taladegib improved lung function and reversed key measures of lung fibrosis (not just slowed it), and it became the first and only investigational IPF therapy to receive PRIME designation from the European Medicines Agency.
What makes Endeavor Biomedicines, Inc. notable?
Endeavor BioMedicines was founded in 2018 by John Hood and Miguel de los Rios and has raised over $676 million, including a $132.5 million Series C led by AyurMaya, an affiliate of Matrix Capital Management.
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.